Myanmar Medical Device Registration: Full Process Overview

1. Key takeaways

The complete pathway for medical device registration in Myanmar can be summarised in six steps: (1) confirm the risk classification → (2) appoint a local authorised representative → (3) prepare the technical documentation → (4) submit electronically → (5) undergo technical review and deficiency responses → (6) obtain the certificate and verify the listing. Among these, step (2) is a statutory step that overseas manufacturers cannot omit, and step (4) must be completed through the Myanmar FDA official electronic submission system at https://esubmission.fda.gov.mm/.

GRZAN note: step (3) (document preparation) and step (4) (account setup and verification configuration) can proceed in parallel in terms of timing, but step (2) must be completed before step (4) — because the submission account is held in the name of the AR, and without an AR there is no account. The pathway is 6 steps long, of which 1 step (appointment of the AR) cannot be omitted and 1 step (2FA configuration) must be brought forward. Treating these dependencies explicitly at project kickoff prevents the most common sequencing errors observed in practice.

2. Legal basis

3. Expert insights

Insight 1: there is a mandatory sequencing relationship between step (2) and step (4). The submission account is held in the name of the AR; if the AR has not been determined, the account cannot be opened, and if the account is not opened, the submission cannot be made. This chain makes the determination of the AR the first node on the critical path of the entire project, and any delay in selecting the AR is transmitted proportionally to the certification date. Companies should therefore treat AR selection as a procurement decision with the same rigour as a technical milestone, evaluating candidates for responsiveness, regulatory experience and willingness to accept post-market reporting duties.

Insight 2: step (3) and step (4) can run in parallel, and this is the main opportunity to compress the timeline. Document preparation typically takes several weeks, while account registration and 2FA configuration take several days. The time saved by running the two in parallel depends on the responsiveness of the AR, which is why writing the AR’s response times into the service agreement is worthwhile.

Insight 3: the deficiency-response stage in step (5) is the main source of timeline volatility. During review, the FDA may request supplementary information and clarifications. The number and scale of deficiency requests directly determine the actual timeline, and the deficiency risk depends mainly on the completeness and consistency of the documents at first submission. Every deficiency round adds administrative handling time on both sides, so the return on investing in a thorough first dossier is direct and measurable.

Insight 4: the listing verification in step (6) is often overlooked. After obtaining the certificate, the company must confirm that the listing details match the import documents (invoice, packing list, batch numbers). An oversight at this stage only surfaces at the customs clearance stage, when the cost of correction rises significantly. A simple cross-check of the certificate details against the commercial documents before the first shipment removes this risk almost entirely.

Insight 5: the three-step architecture means pre-market and post-market cannot be separated. The authorities have incorporated post-market surveillance into the import control system, so companies must plan vigilance and reporting capabilities at the same time as they design their registration strategy. A registration programme that ends at the certificate therefore leaves the second half of the compliance lifecycle unaddressed.

4. Practical recommendations

• Make appointing the AR the first project milestone. Complete the authorised representative agreement before document preparation starts.
• Run document preparation and account registration in parallel. Start portal account opening and 2FA configuration while the dossier is being compiled.
• Prepare the first submission to the highest possible level of completeness. Reducing the probability of deficiency requests is the most effective way to compress the timeline.
• Reserve a dedicated time window for the deficiency-response stage. Do not schedule shipments based on the ideal timeline.
• Verify the consistency of the listing and the import documents immediately after certification. Bring the reconciliation forward to before shipment.

5. Verification checklist

• □ The product risk class (A / B / C / D) has been confirmed
• □ The local authorised representative has been appointed and the letter of authorisation signed
• □ The complete set of technical documents has been assembled
• □ Registration of the e-Submission account has been completed
• □ Two-factor authentication (2FA) has been enabled
• □ The submission has been made through the medical device module and a reference number obtained
• □ An owner and a deadline mechanism for deficiency responses have been established
• □ After certification, the consistency of the listing and the import documents has been verified

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support across Southeast Asia, including Myanmar. Our team prepares the technical dossier to ASEAN CSDT structure, manages submission and deficiency responses with the Myanmar FDA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com